#recurrence-risk

#recurrence-risk

Incyte tops this list due to its rare combination of commercial scale, cash generation, and pipeline depth. The company posted FY2025 revenue of $5.14 billion, up 21.2% YoY, anchored by Jakafi generating $828.2 million in Q4 2025 alone (+7% YoY) and Opzelura delivering $207.3 million (+28% YoY). With $3.58 billion in cash and 14 pivotal clinical trials underway, Incyte offers an acquirer immediate revenue, margin expansion potential, and a deep oncology pipeline spanning KRASG12D, CDK2 inhibition, and mutCALR.

Keytruda, first approved in 2014, belongs to a class of immunotherapy drugs that enable the immune system to attack cancer cells, extending survival for millions and transforming fatal diagnoses into manageable conditions.

The study published in the Lancet analyzed data from 381 patients with platinum-resistant ovarian cancer, revealing a 35% reduction in the risk of death among those treated with relacorilant compared to usual care.

New findings on cancer survival rates offer hope for the more than 2 million Americans diagnosed each year. Seven out of 10 Americans diagnosed with cancer now survive five years or more, according to the American Cancer Society, a 7 percent increase since the mid-1990s, when the rate stood at 63 percent. The survival rate data - from patients diagnosed with cancer between 2015 and 2021 - showed, significantly, that those with high-mortality cancers and advanced diagnoses had the largest gains.

For years, scientists have viewed cancer as a localized glitch in which cells refuse to stop dividing. But a new study suggests that, in certain organs, tumors actively communicate with the brain to trick it into protecting them. Scientists have long known that nerves grow into some tumors and that tumors containing lots of nerves usually lead to a worse prognosis.

Three in four cancer patients in England will beat cancer under government plans to raise survival rates, as figures reveal someone is now diagnosed every 75 seconds in the UK. Cancer is the country's biggest killer, causing about one in four deaths, and survival rates lag behind several European countries, including Romania and Poland. Three-quarters of NHS hospital trusts are failing cancer patients, a Guardian analysis found last year, prompting experts to declare a national emergency.

The cancer was fastacting, and if I'd left it even six months, the outcome could have been much worse,

A report last year found unnecessary surgeries were carried out, cancers were missed and poor standards of care were delivered at the University Hospital of North Durham and Darlington Memorial Hospital. CDDTF said it wanted to support the patients it had let down, including by offering access to psychological support, and to ensure they knew how to make a claim or raise concerns with police.

Smoking, being overweight, and exposure to ultraviolet radiation from the sun and sunbeds are the top preventable causes of cancer, experts have warned. Researchers from the World Health Organisation (WHO) and its International Agency for Research on Cancer (IARC) analysed 30 risk factors that cause cancer, such as smoking, drinking alcohol and air pollution. Using data from across 185 countries, they estimate that about 7.1 million of the 18.7 million new cancer cases diagnosed globally in 2022 were preventable.

These figures represent decades of crucial scientific breakthroughs. From vaccines that prevent cancer to kinder, more targeted treatments. Because of this, thousands more people today can make memories, reach milestones and spend precious time with their loved ones.